Table E1. Baseline Characteristics of NPC patients with or without HDL-C tested

| Characteristics | With HDL-C | Without HDL-C | *p value* |
|---|---|---|---|
| Case (Percentage) | 342 (85.5%) | 58 (14.5%) | |
| Age(y)[mean(range)] | 43.3(18-65) | 41.9(18-62) | 0.092 |
| Sex | | | 0.934 |
| Male | 267 (78.1%) | 45 (77.6%) | |
| Female | 75(21.9%) | 13 (22.4%) | |
| T stage | | | 0.358 |
| T1-2 | 51 (14.9%) | 6 (10.3%) | |
| T3-4 | 291 (85.1%) | 52 (89.7%) | |
| N stage | | | 0.873 |
| N0-1 | 169 (49.4%) | 28 (48.3%) | |
| N2-3 | 173 (50.6%) | 30 (51.7%) | |
| RT Dose(Gy)[median(range)] | 72 (68-78) | 72 (68-78) | 0.401 |
| Treatment Arm | | | 0.096 |
| IC+CCRT | 166 (48.5%) | 35 (60.3%) | |
| IC+RT | 176 (51.5%) | 23 (39.7%) | |

Abbreviations:HDL-C:high-density lipoprotein cholesterol;RT Dose:radiotherapy dose; IC+CCRT:induction chemotherapy plus concurrent chemoradiotherapy; IC+RT: induction chemotherapy plus radiotherapy.

Table E2. Survival of NPC patients with or without HDL-C tested

|  | With HDL-C | Without HDL-C | p value |
|---|---|---|---|
| 5 year OS | 70.7% | 72.4% | 0.563 |
| 5 year FFS | 62.4% | 63.8% | 0.777 |
| 5 year LR-FFS | 85.9% | 88.3% | 0.853 |
| 5 year D-FFS | 70.6% | 68.6% | 0.908 |

Abbreviations: HDL-C: high-density lipoprotein cholesterol; OS: overall survival; FFS: failure free survival; LR-FFS: local-regional failure-free survival; D-FFS: distant failure-free survival.

Table E3. Univariate analysis of different end points

| Varibles | Cases (n) | 5year FFS (%) | p | 5 year OS (%) | p | 5 year LR-FFS (%) | p | 5 year D-FFS (%) | p |
|---|---|---|---|---|---|---|---|---|---|
| Gender | | | 0.01 | | 0.19 | | 0.004 | | 0.183 |
| Male | 267 | 59.3 | | 68.9 | | 82.7 | | 69.5 | |
| Female | 75 | 73.1 | | 77.0 | | 96.9 | | 74.4 | |
| Age | | | 0.52 | | 0.03 | | 0.889 | | 0.727 |
| ≤43 year | 181 | 63.1 | | 74.8 | | 86.0 | | 70.7 | |
| ＞43 year | 161 | 61.5 | | 66.2 | | 85.6 | | 70.4 | |
| T stage | | | 0.72 | | 0.59 | | 0.767 | | 0.956 |
| T1/T2 | 51 | 62.1 | | 74.0 | | 84.0 | | 69.8 | |
| T3/T4 | 291 | 62.4 | | 70.2 | | 86.2 | | 70.7 | |
| N stage | | | 0.31 | | 0.17 | | 0.927 | | 0.102 |
| N0/N1 | 169 | 64.1 | | 72.6 | | 88.0 | | 72.4 | |
| N2/N3 | 173 | 60.8 | | 68.9 | | 83.6 | | 68.8 | |
| Treatment | | | 0.57 | | 0.37 | | 0.676 | | 0.468 |
| IC+CCRT | 166 | 62.3 | | 71.4 | | 84.4 | | 70.8 | |
| IC+RT | 176 | 62.6 | | 70.2 | | 87.3 | | 70.4 | |
| BMI | | | 0.02 | | 0.00 | | 0.845 | | 0.012 |
| <23.0 | 190 | 57.5 | | 65.3 | | 86.8 | | 64.3 | |
| ≥23.0 | 152 | 68.5 | | 77.3 | | 84.8 | | 78.3 | |
| TC | | | 0.24 | | 0.20 | | 0.501 | | 0.105 |
| <200mg/dl | 210 | 60.4 | | 66.3 | | 84.4 | | 68.3 | |
| ≥200mg/dl | 132 | 65.4 | | 77.7 | | 88.2 | | 74.2 | |
| TG | | | 0.66 | | 0.67 | | 0.929 | | 0.340 |
| <150mg/dl | 251 | 61.2 | | 69.2 | | 85.9 | | 68.7 | |
| ≥150mg/dl | 91 | 65.9 | | 75.1 | | 85.9 | | 76.0 | |
| HDL-C | | | 0.01 | | 0.09 | | 0.062 | | 0.148 |
| <40mg/dl | 80 | 52.1 | | 64.7 | | 79.1 | | 65.2 | |
| ≥40mg/dl | 262 | 65.5 | | 72.5 | | 88.0 | | 72.1 | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| LDL-C | | | 0.87 | | 0.96 | | 0.919 | 0.785 |
| <130mg/dl | 227 | 62.2 | | 69.0 | | 85.1 | 70.8 | |
| ≥130mg/dl | 115 | 62.8 | | 74.1 | | 87.5 | 70.1 | |

Abbreviations:IC=induction chemotherapy; CCRT=concurrent chemoradiotherapy; RT=radiotherapy; BMI=body mass index; OS: overall survival;

PFS=progression free survival; FFS=failure free survival; LR-FFS=local-regional failure-free survival; D-FFS=distant failure-free survival; TC=total cholesterol;

TG= triglyceride; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-densitylipoprotein cholesterol